Paul Wallace
Direktor/Vorstandsmitglied bei Stroma Biosciences Ltd.
Aktive Positionen von Paul Wallace
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Stroma Biosciences Ltd.
Stroma Biosciences Ltd. Miscellaneous Commercial ServicesCommercial Services Stroma Biosciences Ltd. is a biopharmaceutical company based in Cambridge, UK. Stroma Biosciences is focused on developing novel anti-stromal therapies to treat cancer by targeting survival signals in the tumour stroma, thereby cutting this important lifeline for cancer cells. The British company's work is focused on mesenchymal stroma cells, which are essential for tumour growth and resistance to cancer therapies. Stroma Biosciences has developed a platform to develop novel first-in-class cancer therapeutics by targeting the stromal compartment. The company has a validated disease-activated platform screening primary tumour samples, and its emerging pipeline includes several stromal targets to treat both solid and haematological malignancies. The company was founded in 2020 by Ingo Ringshausen, Andrew Douglas Moore, and Clive Stanway. | Direktor/Vorstandsmitglied | 01.01.2021 | - |
Karriereverlauf von Paul Wallace
Ehemalige bekannte Positionen von Paul Wallace
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
MEDIVIR AB | Corporate Officer/Principal | 01.01.2000 | 28.02.2015 |
Ausbildung von Paul Wallace
University of Cambridge | Doctorate Degree |
Statistik
International
Vereinigtes Königreich | 3 |
Schweden | 2 |
Operativ
Corporate Officer/Principal | 1 |
Doctorate Degree | 1 |
Director/Board Member | 1 |
Sektoral
Health Technology | 2 |
Consumer Services | 2 |
Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
MEDIVIR AB | Health Technology |
Private Unternehmen | 1 |
---|---|
Stroma Biosciences Ltd.
Stroma Biosciences Ltd. Miscellaneous Commercial ServicesCommercial Services Stroma Biosciences Ltd. is a biopharmaceutical company based in Cambridge, UK. Stroma Biosciences is focused on developing novel anti-stromal therapies to treat cancer by targeting survival signals in the tumour stroma, thereby cutting this important lifeline for cancer cells. The British company's work is focused on mesenchymal stroma cells, which are essential for tumour growth and resistance to cancer therapies. Stroma Biosciences has developed a platform to develop novel first-in-class cancer therapeutics by targeting the stromal compartment. The company has a validated disease-activated platform screening primary tumour samples, and its emerging pipeline includes several stromal targets to treat both solid and haematological malignancies. The company was founded in 2020 by Ingo Ringshausen, Andrew Douglas Moore, and Clive Stanway. | Commercial Services |
- Börse
- Insiders
- Paul Wallace
- Erfahrung